EZH2 and breast cancer: More intriguingly, although EZH2 upregulation presaged poor survival outcome in BC patients, its overexpression may be a protective factor in TNBC patients (HR < 0), which seemed to be contradictory to the former study (Yomtoubian et al., 2020).